（编辑 任世碧） 证券日报网讯 8月13日晚间，百诚医药发布公告称，为提高资金利用率，实现优质资产配置目标，公司 借助专业机构的专业力量，由公司控制的杭州觅鹏企业管理合伙企业（有限合伙）（简称"杭州觅鹏"） 拟参与认购临海市浙生协同生命健康创业投资合伙企业（有限合伙）份额，杭州觅鹏于2025年8月13日 签署《合伙协议》。杭州觅鹏作为有限合伙人，拟以自有资金2，000万元认购对应的出资额。本事项无 需提交董事会和股东大会审议。 ...

百诚医药8月13日晚间发布公告称，为提高资金利用率，实现优质资产配置目标，杭州百诚医药科技股 份有限公司借助专业机构的专业力量，由公司控制的杭州觅鹏企业管理合伙企业（有限合伙）拟参与认 购临海市浙生协同生命健康创业投资合伙企业（有限合伙）份额，杭州觅鹏于2025年8月13日签署《合 伙协议》。杭州觅鹏作为有限合伙人，拟以自有资金2000万元认购对应的出资额。 本次与专业机构共同投资符合《深圳证券交易所上市公司自律监管指引第7号—交易与关联交易（2025 年修订）》第四十一条相关规定，本次认购份额的私募基金为与主营业务相关的投资基金。 （文章来源：每日经济新闻） ...

格隆汇8月13日丨百诚医药(301096.SZ)公布，为提高资金利用率，实现优质资产配置目标，杭州百诚医 药科技股份有限公司借助专业机构的专业力量，由公司控制的杭州觅鹏企业管理合伙企业(有限合伙)(简 称"杭州觅鹏")拟参与认购临海市浙生协同生命健康创业投资合伙企业(有限合伙)份额，杭州觅鹏于2025 年8月13日签署《合伙协议》。杭州觅鹏作为有限合伙人，拟以自有资金2,000万元认购对应的出资额。 ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-037 杭州百诚医药科技股份有限公司 关于公司控制的合伙企业认购私募基金份额的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本次交易概述 为提高资金利用率，实现优质资产配置目标，杭州百诚医药科技股份有 限公司（以下简称"公司"）借助专业机构的专业力量，由公司控制的杭州 觅鹏企业管理合伙企业（有限合伙）（以下简称"杭州觅鹏"）拟参与认购 临海市浙生协同生命健康创业投资合伙企业（有限合伙）份额，杭州觅鹏于 2025年8月13日签署《合伙协议》。杭州觅鹏作为有限合伙人，拟以自有资金 2,000万元认购对应的出资额。 本次投资未达到《公司章程》和《对外投资管理制度》规定的审议标准， 无需提交董事会和股东大会审议。本次投资资金来源于杭州觅鹏自有资金， 不构成关联交易，不构成重大资产重组。 本次与专业机构共同投资符合《深圳证券交易所上市公司自律监管指引 第7号—交易与关联交易（2025年修订）》第四十一条相关规定，本次认购份 额的私募基金为与主营业务相关的投资基金。 二、合作方基本情况 （一）普通 ...

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Investment Rating - The report maintains a strong investment rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [7]. Core Insights - The report highlights the recent policy push for brain-computer interface (BCI) technology, emphasizing the potential for a trillion-dollar market opportunity. The government aims to cultivate 2-3 global leading companies in this field by 2030, showcasing the urgency to position within this emerging industry [4][16][17]. Market Review - The CITIC Pharmaceutical Index fell by 0.8% during the week of August 4-8, 2025, underperforming the CSI 300 Index by 2.0 percentage points. However, since the beginning of 2025, the CITIC Pharmaceutical and Biotechnology Index has risen by 21.8%, outperforming the CSI 300 Index by 17.5 percentage points [3][31]. - The top five performing stocks during this week included Nanmo Biology (+42.5%), Haichen Pharmaceutical (+41.3%), Sainuo Medical (+39.5%), Chengyi Pharmaceutical (+35.8%), and Dabo Medical (+31.5%) [3][48]. Investment Focus - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as medical devices, which are expected to see a policy turning point. The report encourages identifying high-performing stocks as companies begin to disclose mid-year results [5][16]. - Specific companies to watch include Mailland, Xiangyu Medical, Chengyitong, Innovation Medical, and Sanbo Brain Science, which are positioned well within the BCI sector [4][16][17]. Policy Developments - Recent policies from seven ministries, including the Ministry of Industry and Information Technology, outline a clear development roadmap for BCI technology, covering aspects from technical breakthroughs to global competitiveness [4][18][22]. - By 2027, key technological breakthroughs are expected, with the establishment of an advanced technical and industrial system. The BCI market is projected to grow significantly, with the global medical BCI market expected to reach $40 billion by 2030 and $145 billion by 2040 [22][23]. Company Developments - Notable companies in the BCI space include: - **Qiangnao Technology**: Focused on non-invasive BCI, received FDA approval for its smart bionic hand. - **Nerve Tiger Technology**: Achieved real-time motion decoding and language understanding with its invasive BCI technology. - **Mikron Medical**: Developing a range of non-invasive BCI products and collaborating with hospitals for research [29][30]. This summary encapsulates the key points from the industry report, focusing on investment opportunities, market performance, and policy developments within the pharmaceutical and biotechnology sectors, particularly in relation to brain-computer interfaces.

8月8日，百诚医药大宗交易成交28.62万股，成交额1653.09万元，占当日总成交额的8.68%，成交均价 57.76元，较市场收盘价57.81元折价0.09%，其中最高成交价57.81元，最低成交价57.61元。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-08-08 | 301096 | 百诚医药 | 57.81 | 21.43 | | 1,238.87 东北证券股份有限 | 东北证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州教工路证 | | | | | | | | 券营业部 | 券营业部 | | 2025-08-08 | 301096 | 百诚医药 | 57.61 | 7.19 | 414.22 | 东北证券股份有限 | 华宝证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州学院路证 | | ...

Group 1 - The core point of the announcement is the decision by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. to use part of the raised funds to permanently supplement its working capital, amounting to RMB 363.87 million [1][2]. - The decision was made during the third meeting of the fourth supervisory board held on August 4, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. - The use of the funds is aimed at reducing financial costs, enhancing operational efficiency, and improving profitability, while ensuring that it does not affect the construction of investment projects or the company's daily operations [1][2]. Group 2 - The proposal to use the raised funds requires approval from the company's shareholders' meeting, with a voting result of 3 votes in favor, 0 against, and 0 abstentions [2]. - The decision aligns with the regulations set forth in the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant guidelines, ensuring no harm to the interests of the company or minority shareholders [1].

证券代码：301096 证券简称：百诚医药 公告编号：2025-033 （一）审议通过《关于部分超募资金永久补充流动资金的议案》 为提高募集资金的使用效率、满足公司流动资金需求，根据《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公 司募集资金监管规则》等规定，公司拟使用首次公开发行股票的超募资金 保荐机构就本议案发表了核查意见。 杭州百诚医药科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第四届董事会第三次会 议于 2025 年 8 月 4 日（星期一）在公司会议室以现场结合通讯的方式召开。会 议通知已于 2025 年 7 月 30 日通过邮件的方式送达各位董事。本次会议应出席董 事 9 人，实际出席董事 9 人（其中 3 位董事以通讯方式出席会议）。 会议由董事长楼金芳主持，监事、高级管理人员列席。会议召开符合有关法 律、法规、规章和《公司章程》的规定。经各位董事认真审议，会议形成了如下 决议： 二、董事会会议审议情况 具体内容详见 ...

（文章来源：证券日报） 证券日报网讯 8月4日晚间，百诚医药发布公告称，公司第四届董事会第三次会议审议通过了《关于部 分超募资金永久补充流动资金的议案》《关于提请召开2025年第二次临时股东大会的议案》。 ...